ArticleJournal of translational medicine2014

Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition.

Jie Zha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.